PAA1

LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS CO-MORBIDITIES FOR SOCIETY AND EMPLOYERS
Bachert C¹, Demarteau N^2
1 Ghent University Hospital, Belgium; ² UCB pharma, Braine-l’Alleud, Belgium

PAA2

PUBLIC HEATH SYSTEM EXPENSES ON CHILDREN’S ATOPIC DERMATITIS TREATMENT IN VLADIVOSTOK CITY
Derkach V, Prosekova E
Far East Branch of Scientific Research Institute of Clinic Immunology, Vladivostok, Russia

PAA3

RESOURCE USE IN PATIENTS WITH EXACERBATIONS OF ASTHMA WITH DIFFERENT UNDERLYING DEGREES OF SEVERITY IN FIVE EUROPEAN COUNTRIES
Piercy J¹, Benford M², Milligan G², Karavali M^2
1 Adelphi Group, Bollington, Cheshire, UK; ² Adelphi Group Products, Bollington, Cheshire, UK

PAA4

A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF SALMETEROL AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
Hetnal M¹, Plisko R¹, Landa K¹, Glogowski C², Gierczynski J^2
1 HTA Consulting, Krakow, Poland; ² GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland

PAA5

A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF FLUTICASONE AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
Hetnal M¹, Plisko R¹, Landa K¹, Glogowski C², Gierczynski J^2
1 HTA Consulting, Krakow, Poland; ² GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland

PAA6

IMPACT OF A DISEASE MANAGEMENT PROGRAM ON CONTROL OF ASTHMA IN NORMANDY
Launois R¹, Salmeron S², Lançon F³, Perez V⁴, Gailhardou M³, Roy M⁴, Magar Y⁵, Queniart-Stojanovic M³, Godard P^6
1 REES France, Paris, France; ² Hopital Saint Joseph, Paris, France; ³ Fedialis Medica Groupe GSK, Marly Le Roi, France; ⁴ Caisse Primaire D’Assurance Maladie D’Evreux, Evreux, France; ⁵ EduSanté, Vanves, France; ⁶ Centre Hospitalier Universitaire (C.H.U), Montpellier, France

PAA7

A COMPARISON OF TWO APPROACHES TO ESTIMATE ANNUAL MEDICATION COSTS IN THE KORA ASTHMA AND ALLERGY STUDY
Holle R, Stark R, Behrend C, John J
GSF - Research Centre for Environment and Health, Neuherberg, Germany

PAA8

WITHDRAWN

PAA9

WITHDRAWN

PAR1

THE BURDEN OF ANKYLOSING SPONDYLITIS IN AUSTRALIA: AN EPIDEMIOLOGICAL AND COST OF ILLNESS MODEL
Stynes G¹, Adams J², Tilden D¹, Garrett S³, Wilson J^2
1 M-TAG Limited, Hammersmith, UK; ² M-TAG Pty Limited, Chatswood, NSW, Australia; ³ Schering-Plough Pty Limited, Baulkham Hills, Australia

PAR2

THE TOTAL COST OF TREATMENT AND THE COST-EFFECTIVENESS OF VALDECOXIB VS DICLOFENAC IN THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS (OA) OF THE HIP AND/OR KNEE
von Scheele B¹, Davis KH², Gaffney L³, Niculescu L⁴, Verburg KM^5
1 RTI Health Solutions, Södra Sandby, Sweden; ² RTI Health Solutions, Research Triangle Park, NC, USA; ³ RTI Health Solutions, Manchester, UK; ⁴ Pfizer Inc, New York, NY, USA; ⁵ Pfizer Inc, Ann Arbor, MI, USA

PAR3

QUANTIFYING DISEASE SEVERITY AS A DETERMINANT OF COSTS AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN AUSTRALIA
Tilden D¹, Stynes G¹, Adams J², Garrett S^3
1 M-TAG Limited, Hammersmith, UK; ² M-TAG Australia Pty Ltd, Chatswood, NSW, Australia; ³ Schering-Plough Pty Limited, Baulkham Hills, Australia

PAR4

THE COART STUDY: THE COST OF OSTEOARTHRITIS IN FRANCE BETWEEN 1991 AND 2002
Le Pen C¹, Reygrobellet C¹, Gerentes I^2
1 Aremis Consultants and Paris Dauphine University, Paris, France; ² Negma-Lerads Laboratories, Paris, France

PAR5

MESSAGE: AN OBSERVATIONAL POST-LAUNCH STUDY TO ASSESS EFFECTIVENESS AND COST OF SUPLASYN® IN PATIENTS WITH KNEE OSTEOARTHRITIS
Le Pen C¹, Ligier M², Priol G², Maurel F², Bacri AM³, Giret d’Orsay G³, Riviere M⁴, Bard H⁵, Mazieres B^6
1 Aremis Consultants and Paris Dauphine University, Paris, France; ² Aremis Consultants, Paris, France; ³ Chiesi, France; ⁴ Bioniche, Canada; ⁵ Rheumatologist, Paris; ⁶ Rheumatology Department Rangueil Hospital, Toulouse, France

PAR6

ECONOMIC EVALUATION OF THERAPY WITH NSAID AND WITH COX-2 IN SUBJECTS AGED 66 YEARS OR MORE
Santoni L¹, Da Deppo L², Mantovani LG^1
1 University of Milan, Milan, Italy; ² Pfizer Italia srl, Rome, Italy

PAR7

FIBROMYALGIA COST OF CARE
de Portu S¹, Stisi S², Fedrighi S¹, Rossetti F¹, Mantovani LG^1
1 University of Milan, Milan, Italy; ² Hospital G.Rummo, Benevento, Italy

PAR8

HEALTH ECONOMIC EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH ADALIMUMAB
Vanoverbeke N¹, Annemans L¹, Cauchie P², Hendrickx E^2
1 HEDM, Meise, Belgium; ² Abbott, Ottignies, Belgium

PAR9

A COST MINIMISATION ANALYSE FOR STUDYING THE EFFICIENCY OF BIOLOGIC THERAPIES (BT) IN RHEUMATOID ARTHRITIS (RA). OVERVIEW FOR THE SPANISH SETTING
Badia X¹, Serrano D¹, Magaz S^2
1 Health Outcomes Research Europe, Barcelona, Barcelona, Spain; ² Health Outcomes Policy and Economics, Barcelona, Spain

PAR10

PATTERNS OF DOSING WITH ADALIMUMAB AMONG COMMERCIALLY INSURED PATIENTS
Ollendorf DA, Lidsky L, Zhao J
PharMetrics, Inc, Watertown, MA, USA

PAR11

A COST EFFICACY ANALYSIS ON ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS
Singh G¹, Tandon N², Bala M^2
1 Stanford University Medical School, Palo Alto, CA, USA; ² Centocor, Inc, Horsham, PA, USA

PAR12

HOW ADEQUATE DO RA-PATIENTS REPORT INDIRECT COSTS? – THE EXAMPLE OF A GERMAN COHORT
Mittendorf T¹, Merkesdal S², Greiner W¹, Ruof J^2
1 University of Hannover, Hannover, Germany; ² Medical School of Hannover, Hannover, Germany

PAR13

COST-EFFECTIVENESS OF VALDECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN THE UK (UK) AND GERMANY
Alten RH¹, von Scheele B², Gaffney L³, Maciver F³, Niculescu L^4
1 Schlossparkklinik, Berlin, Germany; ² RTI Health Solutions, Södra Sandby, Sweden; ³ RTI Health Solutions, Manchester, UK; ⁴ Pfizer Inc, New York, NY, USA

PAR14

COSTS OF RA IN GERMANY ON A MICRO-COSTING LEVEL
Mittendorf T¹, Ruof J^2
1 University of Hannover, Hannover, Germany; ² Medical School of Hannover, Hannover, Germany

PAR15

A COMPARISON OF COST OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY: RESULTS OF THE IERI STUDY GROUP
De Portu S¹, Ferraccioli G², Sarzi-Purrini P³, Fiocco U⁴, Montecucco C⁵, Valesini A⁶, Canesi B⁷, Leardini G⁸, Mecchia M⁹, Mantovani LG^1
1 University of Milan, Milan, Italy; ² Università Cattolica del Sacro Cuore, Rome, Italy; ³ Ospedale L. Sacco, Milano, Italy; ⁴ Università di Padova, Padova, Italy; ⁵ Università di Pavia, IRCCS, Policlinico S.Matteo, Pavia, Italy; ⁶ Università La Sapienza, Policlinico Umberto I, Roma, Italy; ⁷ Ospedale Niguarda, Milano, Italy; ⁸ ULSS12 Venezia, Venezia, Italy; ⁹ Wyeth, Aprilia, Aprilia, Italy

PAR16

CO-PAYMENTS IN RHEUMATOID ARTHRITIS OBSERVED IN A GERMAN COHORT
Mittendorf T¹, Hülsemann JL², Ruof J^2
1 University of Hannover, Hannover, Germany; ² Medical School of Hannover, Hannover, Germany

PAR17

LINGUISTIC ADAPTATION AND VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS) INTO SPANISH
Ruiz M¹, Campillo MA², Monfort J², Pardo A¹, Rejas J³, Soto J^3
1 Department of Methodology, College of Psychology, Universidad Autónoma, Madrid, Spain; ² Department of Rheumatology, Hospital del Mar, Barcelona, Spain; ³ Pfizer SA, Alcobendas, Madrid, Spain

PAR18

ASSESSMENT OF HEALTH STATUS IN A NATIONAL SAMPLE OF U.S. OSTEOARTHRITIC PATIENTS
Gandra SR, Lawrence LW, Humble LJ
The University of Louisiana at Monroe, Monroe, LA, USA

PAR27

ASSESMENT OF QUALITY OF LIFE (QOL) IN ADULTS WITH JUVENILE IDIOPATIC ARTHRITIS (AIJ) DIAGNOSIS IN MéXICO: THE DISABILITY IMPACT

Guzmán Vázquez S¹, Soto-Molina H², Cháidez-Rosales P³, Ilizaliturri-Sánchez VM V³, Duarte-Salazar C³, Nieves-Silva J³, Valero González F³, Aguilera-Zepeda J³, Garduño Espinosa J^2
1 Universidad Autónoma del Estado de México, Toluca, Mexico; ² Instituto Mexicano Seguro Social, Col. Juarez, Mexico; ³ National Rehabilitation Center (CNR), Col. Arenal de Guadalupe, Mexico

PAR28

ASSESSING INTANGIBLES IN BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS (RA). A WILLINGNESS TO PAY (WTP) STUDY IN SPANISH PATIENTS.

Badia X¹, Serrano D¹, Magaz S^2
1 Health Outcomes Research Europe Group, Barcelona, Spain; ² Health Outcomes Policy and Economics, Barcelona, Spain

PAR19

SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH RHEUMATOLOGISTS IN 2003
Thomas E¹, Blotman F¹, Myon E², Taieb C^2
1 CHU Montpellier, Montpellier, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PAR20

PEOPLES PREFERENCES FOR WHO SHOULD GET THE NEXT JOINT REPLACEMENT
Davies LM, Payne K, Fargher EA
University of Manchester, Manchester, UK

PAR21

CROSS-SURVEY OF RHEUMATOLOGISTS AND GP AWARENESS AND KNOWLEDGE OF FIBROMYALGIA
Blotman F¹, Thomas E¹, Myon E², Taieb C^2
1 CHU Montpellier, Montpellier, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PAR22

FIBROMYALGIA SYNDROM: A FRENCH EPIDEMIOLOGICAL SURVEY
Myon E, Taieb C
Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PAR23

SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH GENERAL PRACTITIONERS
Thomas E¹, Blotman F¹, Myon E², Taieb C^2
1 CHU Montpellier, Montpellier, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PAR24

RELATIONSHIPS BETWEEN AGE, NUMBER OF PRESCRIPTIONS, AND CO-MORBIDITIES AMONG VA PATIENTS
Raisch DW, Harris CL, Netravali S, Campbell H
VA Cooperative Studies Program, Albuquerque, NM, USA

PAR25

CROSS-VALIDATION OF A NEW QUESTIONNAIRE DESIGNED TO PREDICT FUTURE RISK OF NSAID-INDUCED GASTROINTESTINAL EVENTS
Livengood K, Ambegaonkar A, Craig T
Pfizer Inc, New York, NY, USA

PAR26

COST-UTILITY OUTCOMES SIMULATION MODEL FOR OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA) PATIENTS (COSMO): DEVELOPMENT AND VALIDATION OF A PHARMACOECONOMIC MODEL
Niculescu L¹, Lising AW², Neumann PJ^3
1 Pfizer Inc, New York, NY, USA; ² Dymaxium Inc, Toronto, ON, Canada; ³ Harvard School of Public Health, Boston, MA, USA

PCN1

COST-EFFECTIVENESS OF APREPITANT GIVEN WITH STANDARD ANTIEMETICS IN PATIENTS RECEIVING CHEMOTHERAPY IN OFFICE-BASED SETTINGS IN GERMANY
Ehlken B¹, Ihbe-Heffinger A², Bernard R², Berger K³, Pellissier JM⁴, Deuson R^5
1 MERG, Medical Economics Research Group, Munich, Germany; ² Klinikum rechts der Isar, Technische Universität München, Munich, Germany; ³ MERG Medical Economics Research Group, Munich, Germany; ⁴ Merck Research Laboratories, St. Charles, IL, USA; ⁵ Merck & Co., Inc, Whitehouse Station, NJ, USA

PCN2

COST-EFFECTIVENESS OF IMATINIB (GLEEVEC) AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
El Ouagari K¹, Talbot W¹, Baladi JF^2
1 Novartis Pharmaceuticals, Dorval, QC, Canada; ² Novartos Pharmaceuticals, Florham Park, NJ, USA

PCN3

COST-EFFECTIVENESS OF BORTEZOMIB (VELCADE) FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Bagust A¹, Haycox A¹, Mujica-Mota R¹, Dhawan R², Dubois D^3
1 University of Liverpool, Liverpool, UK; ² Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA; ³ Johnson & Johnson Pharmaceutical Services LLC, Beerse, Belgium

PCN4

COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER
Ryan J¹, Hirsch M², Knight H^1
1 Mapi Values Ltd, Macclesfield, Cheshire, UK; ² AstraZeneca UK Ltd, Macclesfield, Cheshire, UK

PCN5

COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Brown R¹, Benedict A¹, Mansel RE^2
1 MEDTAP International Inc, London, UK; ² University of Wales College of Medicine, Cardiff, UK

PCN6

HOSPITALIZATION COSTS OF PATIENTS WITH INFECTIONS WHO HAVE LUNG CANCER OR NEUTROPENIA IN SWEDEN – A RETROSPECTIVE DATABASE STUDY
Myren KJ
Eli Lilly Sweden AB, Solna, Sweden

PCN7

THE LIFETIME COST OF GEFITINIB (‘IRESSA’) IN TREATING PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)
Haiderali A¹, Chin W^2
1 AstraZeneca Canada Inc, Mississauga, Ontario, Canada; ² Axia Research Inc, Salt Lake City, UT, USA

PCN8

COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UK
De Cock E¹, Hutton J¹, Barrett-Lee P², Canney P³, Body JJ⁴, Neary M⁵, Lewis G^6
1 MEDTAP International Inc, London, UK; ² Velindre Cancer Centre, Cardiff, UK; ³ Western Hospital, Glasgow, UK; ⁴ Université Libre de Bruxelles, Brussels, Belgium; ⁵ Hoffmann-La Roche Inc, Nutley, NJ, USA; ⁶ Roche Products Limited, Welwyn Garden City, Herts, UK

PCN9

A TIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BREAST CANCER PATIENTS IN THE UK
Wardley A¹, Body JJ², Neary M³, Lewis G^4
1 Christie Hospital, Manchester, UK; ² Université Libre de Bruxelles, Brussels, Belgium; ³ Hoffmann-La Roche Inc, Nutley, NJ, USA; ⁴ Roche Products Limited, Welwyn Garden City, Herts, UK

PCN10

COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER DIAGNOSIS WITH CAD (COMPUTER AIDED DETECTION)
Heinen-Kammerer T, Motzkat K, Rychlik R
Institute of Empirical Health Economics, Burscheid, Germany

PCN11

COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCER WITH BONE METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK
De Cock E¹, Hutton J¹, Barrett-Lee P², Canney P³, Body JJ⁴, Neary M⁵, Lewis G^6
1 MEDTAP International Inc, London, UK; ² Velindre Cancer Centre, Cardiff, UK; ³ Western Hospital, Glasgow, UK; ⁴ Université Libre de Bruxelles, Brussels, Belgium; ⁵ Hoffmann-La Roche Inc, Nutley, NJ, USA; ⁶ Roche Products Limited, Welwyn Garden City, Herts, UK

PCN12

COST EFFECTIVENESS OF AN ASPIRIN CHEMOPREVENTION AND/OR COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER
Gerlier L¹, Launois R¹, Deyra J², Traissac L³, Chaussade S⁴, Benamouzig R^3
1 REES France, Paris, France; ² APACC, Paris, France; ³ Hôpital Avicenne, Bobigny, France; ⁴ Hôpital Cochin, Paris, France

PCN13

COST-EFFECTIVENESS ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH CISPLATIN-ETOPOSIDE, CISPLATIN-WINORELBINE AND CISPLATIN-GEMCYTABINE
Skowron A, Brandys J
Jagiellonian University, Cracow, Poland

PCN14

ALCEA (ADVANCED LUNG CANCER ECONOMIC ASSESSMENT)
Mangone M¹, Negrini C², Perrone F³, Portalone L⁴, Salvati F⁵, Zorat PL^6
1 Astrazeneca Italy; ² PBE Consulting, Verona, Italy; ³ Istituto Nazionale Tumori, Napoli, Italy; ⁴ Ospedale C.Forlanini Roma, Italy; ⁵ Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy; ⁶ P.O.Cà Foncello, Treviso, Italy

PCN15

GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT2): A PATIENT-LEVEL COST COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN FRANCE
Launois R¹, Avoinet S², Le Lay K¹, Tilden D³, Bhalla S⁴, Kielhorn A⁵, Chemali N^2
1 REES France, PARIS, France; ² LILLY, Suresnes, France; ³ M-TAG, Chatswood, New Zealand; ⁴ European Health Outcomes Research, Windlesham, UK; ⁵ EDOS Team Leader, Windlesham, Surrey, UK

PCN16

COMPARATIVE COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN GERMANY
Bischoff H¹, Hamann M², Stynes G³, Bhalla S⁴, Tilden D³, Kielhorn A^4
1 Stabsstelle Medizinisches Management, Heidelberg, Germany; ² Eli Lilly – Germany, Bad Homburg, Germany; ³ M-TAG Limited, Hammersmith, UK; ⁴ Eli Lilly, Windlesham, Surrey, UK

PCN17

DOES GEMCITABINE PLUS CISPLATIN PROVIDE VALUE FOR MONEY IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN THE UK?
Watkins J¹, Kielhorn A², Bhalla S², Tilden D³, Stynes G^3
1 Eli Lilly, Basingstoke, UK; ² Eli Lilly, Windlesham, Surrey, UK; ³ M-TAG Limited, Hammersmith, UK

PCN18

A COST COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY
Kielhorn A¹, Stynes G², Bhalla S¹, Tilden D^2
1 Eli Lilly, Windlesham, Surrey, UK; ² M-TAG Limited, Hammersmith, UK

PCN19

NEW TARGETED THERAPY FOR PATIENTS WITH PREVIOUSLY-TREATED ADVANCED NON-SMALL CELL LUNG CANCER – GEFITINIB (‘IRESSA’)
de Peuter R¹, Antonisse A², van Loon J¹, Brown J^3
1 Mapi Values, Houten, Netherlands; ² AstraZeneca BV, Zoetermeer, Netherlands; ³ AstraZeneca, Macclesfield, Cheshire, UK

PCN20

COSTS OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER IN SPAIN USING GEMCITABINE IN COMBINATION WITH CISPLATIN: A COMPARISON WITH OTHER 2^ND GENERATION NOVEL AGENTS
Kielhorn A¹, Dilla T², Stynes G³, Tilden D³, Bhalla S^1
1 Eli Lilly, Windlesham, Surrey, UK; ² Eli Lilly, Madrid, Spain; ³ M-TAG Limited, Hammersmith, UK

PCN21

A PHARMACOECONOMIC MODEL OF THE COST-EFFECTIVENESS OF GEFITINIB (‘IRESSA’) COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN THE UK
Ratcliffe AE¹, Beard S², Wolowacz S^2
1 AstraZeneca, Luton, Bedfordshire, UK; ² RTI Health Solutions, Manchester, UK

PCN22

A SYSTEMATIC EVALUATION OF THE IMPACT OF THE SCREENING INTERVAL ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DIFFERENT CERVICAL CANCER SCREENING TECHNIQUES.
Sroczynski G¹, Aidelsburger P², Wasem J², Voigt K³, Gibis B⁴, Engel J⁵, Hillemanns P⁵, Hölzel D⁵, Goldie SJ⁶, Siebert U^1
1 Harvard Medical School, Boston, MA, USA; ² University of Duisburg-Essen, Duisburg-Essen, Germany; ³ Institute for Medical Informatics, Biostatistics, and Epidemiology, University of Munich, Munich, Germany; ⁴ National Association of Statutory Health Insurance Physicians, Berlin, Germany; ⁵ University of Munich, Munich, Germany; ⁶ Harvard School of Public Health, Boston, USA

PCN23

A COST MINIMIZATION ANALYSIS OF FIRST-LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Le Lay K¹, Riou-França L², Avoinet S³, Chemali N⁴, Vergnenègre A⁵, Launois R^6
1 Rees France, Paris, France; ² ReesFrance, Paris, France; ³ LILLY FRANCE, Suresnes, France; ⁴ Lilly, Suresnes, France; ⁵ Hopital Du Cluzeau, Limoges, France; ⁶ ReesFrance, Paris, FRANCE, France

PCN24

GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIAL (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER IN TAIWAN
Yang CH¹, Wang L², Wang N³, Kielhorn A^4
1 National Taiwan University Hospital, Taipei, Taiwan; ² Protech Pharmaservices Corporation, Taipei, Taiwan; ³ Eli Lilly and Company Taiwan, Taipei, Taiwan; ⁴ Eli Lilly Holdings Limited, Surrey, UK

PCN25

COST-EFFECTIVENESS-ANALYSIS OF THE THERAPY OF STAGE T1-T2 PROSTATE CANCER WITH PERMANENT SEED IMPLANTATION IN COMPARISON WITH RADICAL PROSTATECTOMY
Heinen-Kammerer T, Motzkat K, Rychlik R
Institute of Empirical Health Economics, Burscheid, NRW, Germany

PCN27

PATIENT PREFERENCE FOR ANASTROZOLE AS ADJUVANT HORMONAL THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY
Wilson J¹, Burridge J¹, Gniel J², Maclean A², LeReun C¹, Adams J¹, Davey P^1
1 M-TAG Australia Pty Ltd, Chatswood, NSW, Australia; ² AstraZeneca Australia Pty Ltd, NSW, Australia

PCN28

QUALITY OF LIFE AND SEXUALITY IN PATIENTS WITH RECTAL CANCER
Bestmann B¹, Schmidt C², Kuechler T¹, Kremer B^3
1 Reference Center Quality of Life in Oncology, Kiel, Schleswig-Holste, Germany; ² Department of General and Thoracic Surgery, Kiel, Schleswig-Holste, Germany; ³ University of Kiel, Kiel, Schleswig-Holste, Germany

PCN29

PROSTATE CANCER SPECIFIC SYMPTOMS IN A GERMAN REFERENCE POPULATION
Bestmann B¹, Loetters C², Weidner W², Kuechler T¹, Rohde V^2
1 Reference Center Quality of Life in Oncology, Kiel, Schleswig-Holste, Germany; ² University of Giessen, Giessen, Hessen, Germany

PCN30

IMPROVED TOXICITY PROFILE OF PEMETREXED VS DOCETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS TRANSLATES TO COST SAVINGS IN SPAIN
Stynes G¹, Aristides M¹, Rosell R², Felip E³, Liepa AM^4
1 M-TAG Limited, London, UK; ² Hospital Germans Trias I Pujol, Barcelona, Spain; ³ Hospital General Universitari Vall d’Hebron, Barcelona, Spain; ⁴ Eli Lilly and Company, Indianapolis, IN, USA

PCN31

EVALUATION OF PEMETREXED VERSUS DOCETAXEL IN THE SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER: PATIENT PREFERENCE AND WILLINGNESS-TO-PAY WITH DISCRETE CHOICE CONJOINT ANALYSIS
Brown AJ¹, Aristides M¹, Fitzgerald PE², Liepa AM³, Boyer MJ⁴, Clarke SA^4
1 M-TAG Ltd, London, UK; ² M-TAG Pty Ltd, Chatswood West, New South Wales, Australia; ³ Eli Lilly and Company, Indianapolis, IN, USA; ⁴ Sydney Cancer Centre, Sydney, Australia

PCN32

INSTRUMENTS TO MEASURE PATIENT-REPORTED OUTCOMES AND PERCEPTIONS OF CANCER-RELATED FATIGUE: A REVIEW OF THE LITERATURE
Baró E¹, Herdman MJ¹, Gasquet JA², Sanchez J^2
1 3D Health Research, Barcelona, Spain; ² Amgen, Barcelona, Spain

PCN33

HEALTH UTILITY VALUES FOR CANCER RELATED ANAEMIA
Lloyd A¹, Kimberley S¹, Cornes P², Tolley K^3
1 MEDTAP International, London, UK; ² Royal United Hospital Bath, Bath, UK; ³ ORTHO BIOTECH, Buckinghamshire, UK

PCN34

UTILITY ASSOCIATED WITH SEVERITY OF CANCER-RELATED ANAEMIA (CRA): A SOCIETAL VALUATION
Ossa DF¹, Briggs A², Cowell W³, Littlewood T⁴, Sculpher M^5
1 Occam Outcomes, Oxford, UK; ² HERC – University of Oxford, Oxford, UK; ³ Healthcare Management Group – Roche, Welwyn Garden City, UK; ⁴ John Radcliffe Hospital, Oxford, UK; ⁵ University of York, York, UK

PCN35

VALUATION OF SOCIETAL PREFERENCE BETWEEN THERAPIES FOR CANCER-RELATED ANAEMIA (CRA): RECOMBINANT HUMAN ERYTHROPOETIN (RH-EPO) VERSUS BLOOD TRANSFUSION
Ossa DF¹, McIntosh E², Briggs A², Cowell W³, Littlewood T⁴, Sculpher M^5
1 Occam Outcomes, Oxford, UK; ² HERC – University of Oxford, Oxford, UK; ³ Healthcare Management Group – Roche, Welwyn Garden City, UK; ⁴ John Radcliffe Hospital, Oxford, UK; ⁵ University of York, York, UK

PCN36

THE VALUE OF THE USE OF ANASTROZOLE AS AN ALTERNATIVE ADJUVANT THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY
Wilson J¹, Burridge J¹, Gniel J², Maclean A², LeReun C¹, Adams J¹, Davey P^1
1 M-TAG Australia Pty Ltd, Chatswood, NSW, Australia; ² AstraZeneca Australia Pty Ltd, NSW, Australia

PCN37

DIFFERENCES IN TREATMENT PRACTICE, RESPONSE RATES AND COST OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT FOR ANEMIC CANCER PATIENTS: A RETROSPECTIVE ANALYSIS FROM SWEDEN
Persson U¹, Borg S¹, Jansson S¹, Ekman T², Franksson L³, Friesland S³, Larsson AM^4
1 IHE, The Swedish Institute for Health Economics, Lund, Sweden; ² Sahlgrenska University Hospital, Gothenburg, Sweden; ³ Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; ⁴ University Hospital, Malmö, Sweden

PCN38

THE IMPACT OF SCREENING ADHERENCE ON MEDICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN GERMANY – A DECISION ANALYSIS
Sroczynski G¹, Voigt K², Gibis B³, Aidelsburger P⁴, Engel J⁵, Wasem J⁴, Hillemanns P⁵, Hölzel D⁵, Goldie SJ⁶, Siebert U^1
1 Harvard Medical School, Boston, MA, USA; ² Institute for Medical Informatics, Biostatistics, and Epidemiology, University of Munich, Munich, Germany; ³ National Association of Statutory Health Insurance Physicians, Berlin, Germany; ⁴ University of Duisburg-Essen, Duisburg-Essen, Germany; ⁵ University of Munich, Munich, Germany; ⁶ Harvard School of Public Health, Boston, USA

PCN39

QUALITY ASSURANCE IN CANCER CHEMOTHERAPY THROUGH PHARMACEUTICAL CARE DOCUMENTATION
Simons S¹, Hudson SA², Macintyre J³, Maclean M⁴, Jaehde U^1
1 Rheinische Friedrich-Wilhelms-Universitaet Bonn, Bonn, NRW, Germany; ² University of Strathclyde, Glasgow, Glasgow, UK; ³ Western General Hospital, Edinburgh, UK; ⁴ Western Infirmary, Glasgow, UK

PCN40

DISPARITIES IN MEDICAID CANCER EXPENDITURES
Mullins CD, Snyder SE, Wang J, Cooke JL, Baquet CR
University of Maryland, Baltimore, MD, USA

PCN41

ASSESSMENT OF DIFFERENT STRATEGIES FOR DETERMINING DIAGNOSIS AND RESECTABILITY IN PATIENTS WITH SUSPECTED PANCREATIC CANCER
Schink T¹, Boehmig M¹, Hur C², Rosewicz S¹, Wernecke KD¹, Siebert U^2
1 Charité University Hospital, Berlin, Germany; ² Harvard Medical School, Boston, MA, USA

PCN42

POOLING CLINICAL AND COST OUTCOMES: A CASE STUDY OF BEST SUPPORTIVE CARE (BSC) IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC)
McAllister R¹, Meddis D², Jansen J¹, Ryan J¹, Brown J^2
1 MAPI Values Ltd, Bollington, Cheshire, UK; ² AstraZeneca, Macclesfield, Cheshire, UK

PCN43

MAPPING HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENTS INTO GENERIC UTILITY MEASURES (EQ-5D): A CASE STUDY WITH BORTEZOMIB (VELCADE)
Mujica-Mota R¹, Bagust A¹, Haycox A¹, Dhawan R², Dubois D^3
1 University of Liverpool, Liverpool, UK; ² Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA; ³ Johnson & Johnson Pharmaceutical Services LLC, Beerse, Belgium

PCN44

META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS FOR COLORECTAL CANCER
Slivinskas J¹, Gagnon YM¹, Enns R^2
1 Occam Outcomes Ltd, Vancouver, BC, Canada; ² St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada

PCN45

MODELING EFFECT IN PHARMACOECONOMICS ANALYSIS USING ARTIFICIAL NEURAL NETWORKS
Polak S, Skowron A, Brandys J, Mendyk A
Jagiellonian University, Kraków, Maopolska, Poland

PCO1

DRUG USE PROFILES AFTER HOSPITALIZATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE NETHERLANDS AND THE RISK ON RE-HOSPITALIZATION
Janse AFC¹, Breekveldt-Postma NS¹, Erkens JA¹, Sandtmann R², Melilli LE³, Herings RMC^4
1 PHARMO Institute, Utrecht, Netherlands; ² Altana Pharma AG, Konstanz, Germany; ³ Pfizer Inc, New York, NY, USA; ⁴ PHARMO Institute / Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

PCO2

ITEM SELECTION FOR COPD-SPECIFIC UTILITY INSTRUMENT
Meguro M, Jones PW
St George's Hospital Medical School, London, UK

PCO3

DEVELOPMENT OF A COPD SEVERITY SCORE IN CLAIMS DATABASE
Wu EQ¹, Birnbaum HG¹, Cifaldi M², Colice G³, Kang Y^1
1 Analysis Group Inc, Boston, MA, USA; ² Abbott Laboratories, Abbott Park, IL, USA; ³ Washington Hospital Center, Washington, DC, USA

PCV1

THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN TAIWAN.
Yang WC¹, Annemans L², Ng YY¹, Hwang SJ^3
1 Taipei Veterans General Hospital, Taipei, Taiwan; ² Ghent University, Meise, Belgium; ³ Kaohshiung Medical University Hospital, Kaohsiung, Taiwan

PCV2

ACHIEVEMENT OF THE EUROPEAN 1998 LDL-C GOAL BY HYPERCHOLESTEROLAEMIC PATIENTS IN THE STELLAR TRIAL: AN EVIDENCE-BASED MEDICINE (EBM) APPROACH
Edwards SJ, Hadlow S
AstraZeneca UK Ltd, Luton, Bedfordshire, UK

PCV3

TIME TO LDL-CHOLESTEROL GOAL ATTAINMENT IN SPAIN
Olivares Q¹, Mabe I², Nocea G³, Alemao E⁴, Caloto T³, Fosbrook L⁵, Ahumada C⁵, Yin D^4
1 CS Pedro La Mata, Albacete, Spain; ² CS Bidezabal, Vizcaya, Spain; ³ Merck, Sharp & Dohme de España, Madrid, Spain; ⁴ Merck & Co, Whitehouse Station, NJ, USA; ⁵ Schering Plough, Madrid, Spain

PCV4

FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION
Foltanova T¹, Thurzo M², Lietava J², Tumova I¹, Lonn E³, Fodor JG^4
1Faculty of Pharmacy, Comenius University, Bratislava, Slovakia; ² 2-nd Department of Internal Medicine, Comenius University, Bratislava, Slovakia; ³Hamilton University, Hamilton, ON, Canada; ⁴University of Ottawa Heart Institute, Ottawa, Canada

PCV79

THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN CHINA
Hu S¹, Chen W¹, Annemans L^2
1 Fudan University, Shanghai, China; ² HEDM, Meise, Belgium

PCV5

LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL® IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION IN GERMANY
Brüggenjürgen B¹, Ehlken B^2
1 Alpha Care GmbH, Celle, Germany; ² MERG, Medical Economics Research Group, Munich, Germany

PCV6

AN ECONOMIC EVALUATION OF CLOPIDOGREL VS. ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISK ATHEROTHROMBOTIC PATIENTS IN ITALY
Rudelli G¹, Annemans L², Spiesser J³, Novelli M⁴, Walker A⁵, Gabriel S^3
1 Sanofi-Synthelabo, Milan, Italy; ² HEDM, Meise, Belgium; ³ Sanofi-Synthelabo Recherche, Bagneux, France; ⁴ Bristol-Myers Squibb, Roma, Italy; ⁵ Bristol-Myers Squibb, Rueil-Malmaison, France

PCV7

THE COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN POLAND
Pietrasik A¹, Niewada M¹, Spiesser J², Gabriel S^3
1 Medical University of Warsaw, Warsaw, Poland; ² Sanofi-Synthelabo Recherche, Bagneux, France; ³ Sanofi-Synthélabo, Bagneux, France

PCV8

THE ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI): POLISH PERSPECTIVE
Pietrasik A¹, Niewada M¹, Spiesser J², Gabriel S^3
1 Medical University of Warsaw, Warsaw, Poland; ² Sanofi-Synthelabo Recherche, Bagneux, France; ³ Sanofi-Synthélabo, Bagneux, France

PCV9

COST-EFFECTIVENESS ANALYSIS OF ALTEPLASE COMPARED WITH STREPTOKINASE AND ABSENCE OF THROMBOLYTICAL THERAPY FOR MYOCARDIAL INFARCTION
Derkach E, Avxentieva M, Vorobjov P
Moscow medical academy, Moscow, Russia

PCV10

THE COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN: AN ANALYSIS OF PCI-CURE
Lindgren P¹, Stenestrand U², Malmberg K³, Jönsson B^4
1 Stockholm Health Economics, Stockholm, Sweden; ² University Hospital of Linköping, Linköping, Sweden; ³ Karolinska Hospital, Stockholm, Sweden; ⁴ Stockholm School of Economics, Stockholm, Sweden

PCV11

COST EFFECTIVENESS OF ADDING NIASPAN TO ATORVASTATIN TREATMENT IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH DYSLIPIDEMIA IN THE UK
Berger W¹, Roze S², Valentine WJ², Palmer AJ^2
1 Merck KGaA, Darmstadt, Germany; ² CORE Center for Outcomes Research, Binningen/Basel, Switzerland

PCV12

SECONDARY PREVENTION AFTER PCI: THE COST-EFFECTIVENESS OF FLUVASTATIN THERAPY IN THE NETHERLANDS
Chaplin S¹, Scuffham P¹, Alon M², Boom van den G^2
1 University of York, York, UK; ² Novartis Pharma, Arnhem, Netherlands

PCV13

ECONOMIC ASSESSMENT OF EZETIMIBE CO-ADMINISTRATION IN A HUNGARIAN CHD PATIENT COHORT NOT AT CHOLESTEROL GOAL ON SIMVASTATIN MONOTHERAPY
Hoffer G¹, Yin D², Alemao E², Nagy L³, Monori M⁴, Davies GM⁵, Cook JR^5
1 University of Debrecen, Debrecen, Hungary; ² Merck & Co, Whitehouse Station, NJ, USA; ³ MSD Hungary Kft, Budapest XII, Hungary; ⁴ Schering Plough, Budapest, Hungary; ⁵ Merck & Co., Inc, Blue Bell, PA, USA

PCV14

AN ECONOMIC ANALYSIS OF CATHETER ABLATION FOR THE TREATMENT OF VENTRICULAR TACHYCARDIA
Reyes C¹, Hernandez J¹, Duff S², Knight T², Calkins H^3
1 Boston Scientific, San Jose, CA, USA; ² Covance Health Economics & Outcomes Services, Gaithersburg, MD, USA; ³ Johns Hopkins Hospital, Baltimore, MD, USA

PCV15

COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH IN SPAIN: AN ECONOMIC EVALUATION BASED ON THE LIFE TRIAL
Ruilope LM¹, Burke TA², Carides GW³, Nocea G^4
1 Hospital 12 de Octubre, Madrid, Spain; ² Merck & Co, Inc, Whitehouse Station, NJ, USA; ³ Merck Research Labs, Blue Bell, PA, USA; ⁴ MSD Spain, Madrid, Spain

PCV16

EVOLUTION OF PRESCRIPTIONS AND DRUG COSTS IN HYPERTENSION – RESULTS FROM A DATABASE FOLLOW-UP STUDY
Berger W¹, Annemans L^2
1 Merck KgaA, Darmstadt, Germany; ² Ghent University, HEDM, Meise, Belgium

PCV17

COSTS OF HYPERTENSION IN POLAND MEASURED FROM THE THIRD PARTY PAYER PERSPECTIVE IN COMPARISON WITH THE SOCIETAL PERSPECTIVE
Hermanowski T¹, Jaworski R², Czech M², Pachocki R^2
1 Warsaw University of Technology, Warsaw, Poland; ² Servier Polska, Warsaw, Poland

PCV18

COSTS OF HYPERTENSION IN THE ELDERLY IN COMPARISON WITH PATIENTS UNDER 65 IN POLAND
Hermanowski T¹, Jaworski R², Czech M², Pachocki R^2
1 Warsaw University of Technology, Warsaw, Poland; ² Servier Polska, Warsaw, Poland

PCV19

COST-EFFECTIVENESS ANALYSIS OF THE MANAGEMENT OF ARTERIAL HYPERTENSION
Stafilas PC¹, Sarafidis PA¹, Lasaridis AN¹, Aletras VH², Zouka MD^3
1 AHEPA University Hospital, Thessaloniki, Greece; ² Hellenic Open University, Patra, Greece; ³ Aristotle University of Thessaloniki, Thessaloniki, Greece

PCV20

COST EFFECTIVENESS OF ANTIHYPERTENSIVE MONO-THERAPY WITH PERINDOPRIL OR ENALAPRIL IN ELDERLY PATIENTS FROM THE THIRD PARTY PAYER PERSPECTIVE
Hermanowski T¹, Jaworski R², Czech M², Pachocki R^2
1 Warsaw University of Technology, Warsaw, Poland; ² Servier Polska, Warsaw, Poland

PCV21

ECONOMIC EVALUATION OF VARIOUS ANTIHYPERTENSIVE MONOTHERAPIES IN GREECE
Stafilas PC¹, Zouka MD², Sarafidis PA¹, Lasaridis AN¹, Aletras VH^3
1 AHEPA University Hospital, Thessaloniki, Greece; ² Aristotle University of Thessaloniki, Thessaloniki, Greece; ³ Hellenic Open University, Patra, Greece

PCV22

THE COST EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY (HRT) FOR WOMEN WITH MENOPASUAL SYMPTOMS IN SWEDEN
Borgström F¹, Zethraeus N², Johnell O³, Kanis J⁴, Jönsson B^2
1 Stockholm Health Economics, Stockholm, Sweden; ² Stockholm School of Economics, Stockholm, Sweden; ³ Malmö University Hospital, Malmö, Sweden; ⁴ University of Sheffield, Sheffield, UK

PCV23

ACUTE COSTS OF STROKE IN THE UK NATIONAL HEALTH SERVICE IN 2002-2004
Luengo-Fernandez R¹, Gray A¹, Mehta Z², Rothwell P^2
1 Oxford University, Oxford, Oxfordshire, UK; ² Oxford University, UK

PCV24

PHARMACOECONOMIC EVALUATION OF THE CIBIS-II TRIAL
Di Stasi F, Scalone L, Mantovani LG
University of Milan, Milan, Italy

PCV25

SMOKING CESSATION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A COST-EFFECTIVENESS ANALYSIS
Der Kinderen AJ, Franco OH, De Laet C
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

PCV26

THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY
Skedgel CD¹, Goeree R², Anderson DR^1
1 Dalhousie University, Halifax, NS, Canada; ² McMaster University, Hamilton, ON, Canada

PCV27

COST-EFFECTIVENESS OF BUPROPION IN SMOKING CESSATION IN FINLAND
Hahl J, Jormanainen V
GlaxoSmithKline Oy, Espoo, Finland

PCV28

COST-EFFECTIVENESS OF RAMIPRIL IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS: A SWISS PERSPECTIVE
Sendi P¹, Russ W², Battegay E³, Bucher H^1
1 Institute for Clinical Epidemiology, Basel, Switzerland; ² Aventis Pharma AG, Zurich, Switzerland; ³ Outpatient Department of Internal Medicine, Basel, Switzerland

PCV29

COST-EFFECTIVENESS OF REDUCTION IN CARDIOVASCULAR OUTCOMES WITH ATORVASTATIN IN PATIENTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS, TREATED FOR HYPERTENSION: THE ASCOT-LLA STUDY
Lindgren P¹, Buxton MJ², Kahan T³, Poulter N⁴, Dahlöf B⁵, Sever P⁴, Wedel H⁶, Jönsson B^7
1 Stockholm Health Economics, Stockholm, Sweden; ² Brunel University, UXBRIDGE, Middlesex, UK; ³ Karolinska Institutet, Stoockholm, Sweden; ⁴ Imperial College, London, UK; ⁵ Sahlgrenska University Hospital/Östra, Göteborg, Sweden; ⁶ Nordic School of Public Health, Göteborg, Sweden; ⁷ Stockholm School of Economics, Stockholm, Sweden

PCV30

COST-EFFECTIVENESS OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN THE DIAGNOSTIC ASSESSMENT AND MANAGEMENT OF PATIENTS WITH DYSPNEA IN THE EMERGENCY DEPARTMENT
Siebert U, Januzzi JL, Beinfeld MT, Cameron R, Gazelle GS
Harvard Medical School, Boston, MA, USA

PCV31

COST OF IN-PATIENT CARE AFTER ADMISSION FOR WARFARIN ASSOCIATED ADVERSE DRUG REACTIONS
Ofori B¹, Donnan P¹, Goudie B², Timoney A², Davey P^1
1 University of Dundee, Dundee, UK; ² NHS Tayside, Dundee, UK

PCV32

SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS® 1442 – A PROSPECTIVE 3-YEAR PHARMACOECONOMIC STUDY
Rychlik R¹, Pfeil T¹, Daniel D¹, Habs M², Klapper HG^2
1 Institute of Empirical Health Economics, Burscheid, Germany; ² Dr. Willmar Schwabe Arzneimittel, Karlsruhe, Germany

PCV33

MODELING THE ECONOMIC IMPACT OF NEW IMPLANTABLE DEFIBRILLATORS WITH A LONGER LIFETIME
Lamarsalle L¹, Vainchtock A², Le Heuzey JY³, Matalon C⁴, Hazard JR^4
1 GYD nstitute – division of IMS Health, Lyon, France; ² GYD nstitute – division of IMS Health; ³ Hôpital Européen Georges Pompidou; ⁴ Guidant France SAS

PCV34

COST-EFFECTIVENESS OF ANTICOAGULATION WITH BIVALIRUDIN VS. HEPARIN AND GLYCOPROTEIN INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN.
Borg S¹, Persson U¹, Conradson TB², Ericsson K^2
1 Swedish Institute for Health Economics, Lund, Sweden; ² Nycomed Group, DK-4000 Roskilde, Denmark

PCV35

ECONOMIC ASSESSMENT OF SWITCHING TO EZETIMIBE CO-ADMINISTERED WITH SIMVASTATIN IN SPAIN FOR A COHORT OF PATIENTS NOT AT GOAL ON ATORVASTATIN MONOTHERAPY
Davies GM¹, Alemao E², Nocea G³, Yin D², Cook JR^1
1 Merck & Co., Inc, Blue Bell, PA, USA; ² Merck & Co, Whitehouse Station, NJ, USA; ³ Merck, Sharp & Dohme de España, Madrid, Spain

PCV36

ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH STATINS IN ITALY
Bustacchini S¹, Ruffo P¹, Mantovani LG^2
1 Pfizer Italia srl, Rome, Italy; ² University of Milan, Milan, Italy

PCV37

ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY
Schädlich PK¹, Lehmacher W², Huppertz E³, Grewe R³, Brecht JG^1
1 InForMed GmbH – Outcomes Research and Health Economics, Ingolstadt, Bavaria, Germany; ² Institute for Medical Statistics, Informatics, and Epidemiology of the University of Cologne, Cologne, NRW, Germany; ³ Aventis Pharma Deutschland GmbH, Bad Soden am Taunus, Hesse, Germany

PCV38

COSTS OF MYOCARDIAL INFARCTION TREATMENT IN RUSSIAN FEDERATION
Avxentieva M, Vorobjov P, Sura M
Moscow Medical Academy, Moscow, Russia

PCV39

MODELING THE ECONOMIC CONSEQUENCES OF IMPLANTING DUAL CHAMBER VS. SINGLE CHAMBER PACEMAKERS IN THE UK
Caro JJ, Ward AJ
Caro Research Institute, Concord, MA, USA

PCV40

COSTS OF ISCHEMIC STROKE TREATMENT IN RUSSIAN FEDERATION
Avxentieva M, Vorobyov P, Sura M
Moscow medical academy, Moscow, Russia

PCV41

COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF HYPERCHOLESTEROLEMIA IN CATALONIA, SPAIN
Plans-Rubió P
Departament de Sanitat of Catalonia, Barcelona, Spain

PCV42

WITHDRAWN

PCV43

THE IMPACT OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN USAGE ON OUTCOMES OF TREATMENT MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES (ACS) IN RUSSIA
Vorobiov PA¹, Yavelov IS², Pavlov VE^3
1 Russian Society of Pharmacoeconomics and Outcomes Research, Moscow, Russia; ² Scientific Institute of Physical and Chemical Medicine, Moscow, Russia; ³ Aventis Pharma, Moscow, Russia

PCV44

VKA TREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION : COST DATA FROM THE INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT (ISAM)
Drouet L¹, Duru G², Mahé I¹, Bergmann JF¹, Bal dit Sollier C¹, Lamarque H³, Gauchoux R⁴, Woessner M³, Hollowell J^5
1 Hôpital Lariboisière, Paris, France; ² Université C. Bernard Lyon I, Villeurbanne, France; ³ AstraZeneca, Rueil Malmaison, France; ⁴ Naxis, Lyon, France; ⁵ AstraZeneca, Molndal, Sweden

PCV45

A SHORT-TERM RETROSPECTIVE ECONOMIC EVALUATION FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION WITH ANGIOTENSIN II-ANTAGONISTS IN SPAIN.
Calvo C¹, López Paz JE¹, González P², Del Castillo A³, Rejas J^3
1 University Hospital of Santiago de Compostela; ² Euroclin Institute; ³ Health Outcomes Research, Medical Unit, Pfizer SA, Alcobendas, Madrid, Spain

PCV46

SCREENING FOR ABDOMINAL AORTIC ANEURYSM IN MEN. AN ECONOMIC EVALUATION BASED ON A SYSTEMATIC REVIEW OF THE LITERATURE
Wanhainen A¹, Lundkvist J², Bergqvist D¹, Björck M^1
1 Uppsala University Hospital, Uppsala, Sweden; ² Karolinska Institutet, Stockholm, Sweden

PCV47

DECISION ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE
Goehler A¹, Dietz R¹, Osterziel KJ¹, Siebert U^2
1 Charitè Campus Virchow Klinikum, Berlin, Germany; ² Harvard Medical School, Boston, MA, USA

PCV48

ARIAL FIBRILLATION HISTORY AND ATRIOVENTRICULAR BLOCK APPEARANCE IN PATIENTS WITH SINUS NODE DISEASE AND SINGLE CHAMBER ATRIAL PACEMAKER – IMPACT ON COST OF THERAPY
Rucinski P¹, Kutarski A^2
1 Medical University of Lublin, Lublin, Poland, Poland; ² Medical University of Lublin, Lublin, Poland

PCV49

CHRONIC VENOUS DISEASE AND DEPRESSIVE SYMPTOMATOLOGY
Guex JJ¹, Myon E², Marionneau N², Taieb C^2
1 Societe Francaise de Phlebologie, Nice, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PCV50

CHRONIC VENOUS DISEASE: PATIENTS PROFILE
Guex JJ¹, Myon E², Marionneau N², Taieb C^2
1 Societe Francaise de Phlebologie, Nice, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PCV51

CHRONIC VENOUS DISEASE AND HEALTH STATUS
Guex JJ¹, Myon E², Marionneau N², Taieb C^2
1 Societe Francaise de Phlebologie, Nice, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PCV52

VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) QUESTIONNAIRE
Meads DM¹, McKenna SP¹, Doughty NJ², Doward LC¹, Pepke-Zaba J^2
1 Galen Research, Manchester, UK; ² Papworth Hospital NHS Trust, Cambridge, UK

PCV53

TRENDS IN PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION AMONG CHINESE AMERICANS FROM 2001 THROUGH 2004
Chin W¹, Ho-Asjoe H², Mak M³, Wan B⁴, Wong SL^5
1 Beth Israel Medical Center, New York, NY, USA; ² New York University School of Medicine, New York, NY, USA; ³ Oxford Health Plans, New York, NY, USA; ⁴ Charles B. Wang Community Health Center, New York, NY, USA; ⁵ Pfizer Inc, Syosset, NY, USA

PCV54

USE OF VISUAL ANALOGUE SCALE (VAS) AS A METHOD OF DISCRIMINATION FOR PHYSICAL DISABILITY SEVERITY IN STROKE
Banks J¹, Salas M², Netten A^3
1 Health Outcomes Strategy Group, Boston, MA, USA; ² Erasmus University Medical School, Rotterdam, Netherlands; ³ University of Kent at Canterbury, Canterbury, UK

PCV55

DISEASE SPECIFIC VERSUS GENERIC OUTCOME ASSESSMENT IN PULMONARY HYPERTENSION
Meads DM¹, Doughty NJ², McKenna SP¹, Doward LC¹, Pepke-Zaba J^2
1 Galen Research, Manchester, UK; ² Papworth Hospital NHS Trust, Cambridge, UK

PCV56

PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERCHOLESTEROLEMIA AMONG CHINESE AMERICANS
Liu G¹, Mak M², Szeto P², Wong SL^3
1 New York University, New York, NY, USA; ² Oxford Health Plans, New York, NY, USA; ³ Pfizer Inc, Syosset, NY, USA

PCV57

CHRONIC VENOUS DISEASE: COMPLIANCE WITH TREATMENT
Guex JJ¹, Myon E², Taieb C^2
1 Societe Francaise de Phlebologie, Nice, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PCV58

CHRONIC VENOUS DISEASE: CARE IMPACT
Guex JJ¹, Myon E², Marionneau N², Taieb C^2
1 Societe Francaise de Phlebologie, Nice, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PCV59

CHRONIC VENOUS DISEASE: THROUGH BODY MASS INDEX
Guex JJ¹, Myon E², Marionneau N², Taieb C^2
1 Societe Francaise de Phlebologie, Nice, France; ² Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PCV60

TREATMENT OF NEWLY-DIAGNOSED HYPERTENSIVE PATIENTS IN ITALY: A RETROSPECTIVE COHORT STUDY IN PRIMARY CARE
Bustacchini S¹, Mazzaglia G², Sturkenboom MC³, Ruffo P¹, Mantovani LG⁴, Brignoli O⁵, Caputi AP^6
1 Pfizer Italia srl, Rome, Italy; ² Health Search, Italian College of General Practitioners, Florence, Italy; ³ International Pharmacoepidemiology and Pharmacoeconomics Research Center, Desio, Italy; ⁴ University of Milan, Milan, Italy; ⁵ Italian College of General Practitioner, Florence, Italy; ⁶ University of Messina, Messina, Italy

PCV61

THE USE OF INTERNET-BASED TECHNOLOGY TO ASSESS MEDICATION ADHERENCE IN PATIENTS WITH HYPERTENSION AND TO PROVIDE INTERACTIVE HEALTH INFORMATION
Plakogiannis R¹, Wong SL^2
1 Long Island University, Brooklyn, NY, USA; ² Pfizer Inc, Syosset, NY, USA

PCV62

HYPERTENSION CLINIC AND HYPERTENSION SPECIALIST IS A COST-EFFECTIVE TOOL FOR THE DISEASE CONTROL IMPROVEMENT IN BELARUS
Golubev S
Vitebsk Regional Center for Refractory Hypertension, Vitebsk, Belarus

PCV63

OVER-ADHERENCE WITH ANTIHYPERTENSIVE MEDICATIONS AMONG CENTRAL TEXAS VETERANS
Yang M, Vincze G, Barner JC
The University of Texas at Austin, Austin, TX, USA

PCV64

FACTORS ASSOCIATED WITH ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS AMONG VETERANS IN CENTRAL TEXAS
Vincze G, Yang M, Barner JC
The University of Texas at Austin, Austin, TX, USA

PCV65

PERSISTENCE WITH DIFFERENT FORMULATIONS OF THE ANTIHYPERTENSIVE DRUG NIFEDIPINE
Breekveldt N, Herings RMC
PHARMO Institute, Utrecht, Netherlands

PCV66

POOLED EFFICACY OF DISEASE MANAGEMENT PROGRAMS IN PATIENTS WITH CONGESTIVE HEART FAILURE – A SYSTEMATIC REVIEW
Goehler A¹, Dietz R¹, Osterziel KJ¹, Siebert U^2
1 Charitè Campus Virchow Klinikum, Berlin, Germany; ² Harvard Medical School, Boston, MA, USA

PCV67

USE OF CLOPIDOGREL AFTER ISCHEMIC VASCULAR EVENTS IN THE NETHERLANDS
Goettsch WG¹, Herings RMC^2
1 PHARMO Institute, Utrecht, Netherlands; ² PHARMO Institute / Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

PCV68

POPULATION IMPACT OF LOSARTAN USE ON STROKE IN FRANCE
Riou França L¹, Souchet T², Ragot S³, Herpin D⁴, Launois R^1
1 REES France, Paris, France; ² Merck Sharp & Dohme – Chibret, Paris, France; ³ Clinical Research Center, University Hospital, Poitiers, France; ⁴ Department of Cardiology, University Hospital, Poitiers, France

PCV69

ATTITUDES OF OFFICE-BASED PHYSICIANS TOWARDS ANTI-COAGULATION TREATMENT
Burkowitz J¹, Raming B², Brüggenjürgen B^1
1 Alpha Care GmbH, Celle, Germany; ² AstraZeneca GmbH, Wedel, Germany

PCV70

DECISION ANALYSIS AND COSTS OF LOW MOLECULAR WEIGHT HEPARINS : A CASE STUDY IN FRANCE
Launois R, Gerlier L
REES France, Paris, France

PCV71

EFFECT OF STATIN TITRATING ON CHOLESTEROL REDUCTION AND GOAL ATTAINMENT IN ACTUAL CLINICAL PRACTICE IN GERMANY
Rajagopalan S¹, Alemao E², Yin D^2
1 Consultant for Merck and Co, Whitehouse Station, NJ, USA; ² Merck & Co, Whitehouse Station, NJ, USA

PCV72

CHOLESTEROL GOAL ATTAINMENT AMONG PATIENTS TREATED WITH LIPID LOWERING DRUGS IN HUNGARY
Márk L¹, Zámoly K², Alemao E³, Nagy L⁴, Monori M⁵, Yin D^3
1 Békés County Hospital, Gyula, II, Gyula, Hungary; ² Bajcsy-Zsilinszky Hospital, IV, Budapest, Hungary; ³ Merck & Co, Whitehouse Station, NJ, USA; ⁴ MSD Hungary Kft, Budapest XII, Hungary; ⁵ Schering Plough, Budapest, Hungary

PCV73

COSTS ASSOCIATED WITH ALTERNATIVE FETAL CARDIOLOGY REFERRAL MODES: APPLICATION OF PROPENSITY SCORE MATCHING
Mistry H, Young TA, Dowie R
Brunel University, Uxbridge, England

PCV74

A METHOD FOR IDENTIFYING PATIENTS WITH CHRONIC ANGINA FROM ADMINISTRATIVE CLAIMS DATA
Watson JB¹, Lee DW², Kadlubek PJ², Haberman M², Goldberg GA^2
1 CV Therapeutics, Palo Alto, CA, USA; ² Constella Health Strategies, Herndon, VA, USA

PCV75

THE APPLICATION OF TWO ANALYTIC METHODS TO INVESTIGATE THE INFLUENCE OF POOR INR CONTROL ON RISKS OF HOSPITALISATION FOR PATIENTS RECEIVING WARFARIN.
Ofori B¹, Davey P¹, Goudie B², Timoney A², Donnan P^1
1 University of Dundee, Dundee, Scotland, UK; ² NHS Tayside, Dundee, Scotland, UK

PCV76

USING A PATTERN MIXTURE MODEL TO UNDERSTAND THE IMPACT OF NON-RANDOM MISSING DATA IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOING NON-CARDIAC VASCULAR SURGERY
Lee WC¹, Cappelleri JC², Sheikh S², Haider S², Gold KF³, Stephens JM^1
1 Abt Associates Inc, Bethesda, MD, USA; ² Pfizer Inc, Groton, CT, USA; ³ Quanta Scientific, Silver Spring, MD, USA

PCV77

ASSESSING THE LIKELIHOOD OF FRACTURE WITH ORAL ANTI-SPASTICITY MEDICATIONS: A CASE-CONTROL STUDY
Nichol MB¹, Shi S¹, Knight TK¹, Barron RL^2
1 University of Southern California, Los Angeles, CA, USA; ² Allergan Corp, Irvine, CA, USA

PHP1

RETAIL PRICES DECREASED 30% IN FINLAND IN 1994-2003 EVEN BEFORE INTRODUCTION OF GENERIC SUBSTITUTION: A COHORT ANALYSIS
Jormanainen V, Hahl J, Eränkö P
GlaxoSmithKline Oy, Espoo, Finland

PHP2

IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION
Blackburn JC¹, Schumock GT¹, Nutescu EA¹, Walton SM¹, Finley JM², Lewis RK^2
1 University of Illinois at Chicago, Chicago, IL, USA; ² Mercy Resource Management Inc, Naperville, IL, USA

PHP3

APPLICATION OF THE DELPHI TECHNIQUE IN THE DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR USE IN METHADONE MAINTENANCE PROGRAMS
Herdman M¹, Duro P², Ibarz R¹, Rajmil L^3
1 3D Health Research, Barcelona, Spain; ² Catalan Department of Health and Social Services; ³ Catalan Agency for Health Technology Assessment and Research, Barcelona, Spain

PHP4

PERSPECTIVE OF THE GENERIC MARKET IN FRANCE: 2004-2008
Le Pen C¹, Moreau A^2
1 Aremis Consultants and Paris Dauphine University, Paris, France; ² Ratiopharm Laboratories, Paris, France

PHP5

DECISION MAKING IN ITALIAN HEALTH CARE: ARE ECONOMIC STUDIES USED BY DECISION MAKERS?
Fattore G, Torbica A
Bocconi University, Milan, Italy

PHP6

PRESCRIPTION PATTERN OF ALIMENTARY TRACT DRUGS AFTER CHANGES OF DRUG BENEFIT STATUS IN KOREA
Lee EK, Park EJ
Korea Instiute for Health and Social Affairs, Seoul, South Korea

PHP7

THE IMPACT OF PHARMACEUTICAL MARKET COMPETITION ON PRICE AND REIMBURSEMENT STATUS OF PATENTED DRUGS IN THE NETHERLANDS, BELGIUM, FRANCE AND GERMANY
Kooijman H¹, Meijboom M¹, Dieten van H², Eijgelshoven M^2
1 PharMerit, Capelle ad IJssel, Netherlands; ² Dutch Health Care Insurance Board, Amstelveen, Netherlands

PHP36

REIMBURSMENT POLICY IN TURKEY: NEW CONSENSUS

Tulunay FC¹, Gulmez SE², Ergun H^2
1 Ankara University, Ankara, Turkey; ² Ankara University School of Medicine, Ankara, Turkey

PHP10

EMERGENCY DEPARTMENT VISITS FOR INJURIES RESULTING FROM BICYCLE ACCIDENTS: TIME, TYPE AND COST OF INJURY
O'Brien JA¹, Pitoniak-Morse C¹, Jacobs LM^2
1 Caro Research Institute, Concord, MA, USA; ² University of Connecticut Medical School, Farmington, CT, USA

PHP11

PRESCRIBING PATTERNS OF CIPROFLOXACIN AND LEVOFLOXACIN IN AN ITALIAN GERIATRIC HOSPITAL
Busca MR¹, Berto P², Benato G², Cofani C³, Berrè F⁴, Borgia L⁵, Di Muzio M^4
1 Pbe Consulting, Milano, Italy; ² Pbe Consulting, Verona, Italy; ³ Bayer Spa, Milano, Italy; ⁴ I.N.R.C.A. Ospedale, Ancona, Italy; ⁵ Università di Camerino, Falconara Marittima, Italy

PHP12

COST VARIANCES IN G-DRG GROUPS. THE EXAMPLE OF RHBMP-2 IN SPINE FUSION SURGERY
Meisel HJ
BG-Clinic Bergmannstrost, Halle, Germany

PHP13

THE HOSPITAL DIAGNOSTIC THERAPEUTIC PATHWAY OF PATIENTS AFFECTED BY CRITICAL ISCHEMIA OF THE LOWER LIMBS WHICH IS UNRESPONSIVE TO REVASCULARIZATION
Ponzi P¹, Magnoni F², Scarpa F¹, Caprari F¹, Pedrini L^2
1 Fondazione Medtronic Italia, Milano, Italy; ² Ospedale Maggiore, Bologna, Italy

PHP14

ECONOMIC ASPECTS OF INDIVIDUAL TREATMENT IN POLAND - OUT–PATIENT VIEWPOINT
Czech M¹, Horoszewska M², Pachocki R^1
1 Servier Polska, Warsaw, Poland; ² Warsaw University of Technology, Warsaw, Poland

PHP15

PREFERENCES MATTER: UNDERSTANDING DEMAND FOR VOLUNTARY HEALTH INSURANCE
De Allegri M¹, Sanon M², Bridges JFP¹, Sauerborn R^1
1 University of Heidelberg, Heidelberg, Germany; ² Centre de Recherche en Sante' de Nouna, Nouna, Burkina Faso

PHP16

PHARMACOECONOMICS INTRODUCTION IN THE CREATION OF POSITIVE DRUG LIST IN BULGARIA
Petrova G. I GIP¹, Benisheva TVB², Ivanova AD^1
1 Faculty of Pharmacy, Sofia, Bulgaria; ² Ministry of Health, Sofia, Bulgaria

PHP17

MEDICINAL CANNABIS IN THE NETHERLANDS
Janse AFC, Breekveldt N, Erkens JA, Herings RMC
PHARMO Institute, Utrecht, Netherlands

PHP18

INTRODUCING THE 'FOURTH HURDLE' IN THE NEW EUROPEAN UNION MEMBER STATES: THE CASE OF HUNGARY
Gulácsi L¹, Boncz I², Drummond MF^3
1 Budapest University of Economic Sciences and Public Administration, Budapest, Hungary; ² National Health Insurance Fund Administration, Budapest, Hungary; ³ University of York, York, North Yorkshire, UK

PHP19

EFFECTS OF DEVOLUTION OF SUBSIDIES FOR PHARMACEUTICALS IN SWEDEN
Bergstrom G, Karlberg I
Goteborg University, Gothenburg, Sweden

PHP20

PROPER DRUG MANAGEMENT IN PHARMACY – THE ROLE OF PHARMACOECONOMICS AS PERCEIVED BY POLISH PHARMACISTS
Czech M¹, Turczynski R², Pachocki R^1
1 Servier Polska, Warsaw, Poland; ² Warsaw University of Technology, Warsaw, Poland

PHP21

QUALITY ASSESSMENT OF AN AMBULATORY CARE CLINIC BASED COLLABORATIVE CARE APPROACH FOR ACHIEVING THERAPEUTIC GOALS
Brown LM¹, Isetts B^2
1 University of Tennessee, Memphis, TN, USA; ² University of Minnesota, Minneapolis, MN, USA

PHP22

MEDICATION AND SOCIO-ECONOMIC STATUS IN A POPULATION-BASED COHORT STUDY
Moebus S¹, Dragano N², Weyers S^2
1 Medical Faculty, University of Duisburg-Essen, Essen, Germany; ² University of Düsseldorf, Düsseldorf, Germany

PHP23

ANALYSIS OF CLINICAL INTERVENTION DOCUMENTATION BY PHARMACISTS
Steimle T, Meier K, Melzer S
LBK Hamburg, Hamburg, Germany

PHP24

ANALYSIS OF “INNOVATOR” DRUGS FINANCED BY SPANISH NATIONAL HEALTH SERVICE OVER THE PERIOD 1996-2003
Gaspar MD, Modamio P, Lastra CF, Mariño EL
University of Barcelona, Barcelona, Spain

PHP25

WILLINGNESS TO PAY VERSUS OUT OF POCKET PAYMENTS FOR HEALTH SERVICES UTILIZATION IN GREECE
Geitona M¹, Kyriopoulos J², Zavras D², Hatzikou M^3
1 University of Thessaly, Volos, Greece; ² National School of Public Health, Athens, Greece; ³ Boehringer-Ingelheim, Athens, Greece

PHP26

PHYSICIANS'ACTIVITY HETEROGENEITY: AN EMPIRICAL STUDY IN TWO FRENCH REGIONS
Béjean S, Peyron C
University of Burgundy, Dijon, France

PHP27

AGE AND GENDER DISTRIBUTION OF PHARMACEUTICAL EXPENDITURE PER INHABITANT
Gilabert-Perramon A, Magem-Luque D
Catalan Health Service, Barcelona, Spain

PHP28

THE ORGANIZED REGISTER OF CANADIAN HEALTH INFORMATION DATABASES (ORCHID) PROJECT: A RESEARCHER INTERFACE
Gibson D¹, Barrette A¹, Giraudi L¹, Han D², Koutsavlis T³, Schneider A⁴, Robinson K⁵, Potvin K^6
1 Ventana Clinical Research Corporation, Toronto, ON, Canada; ² Wyeth Pharmaceuticals, Markham, ON, Canada; ³ Paladin Labs Inc, Montreal, QC, Canada; ⁴ Eli Lilly Canada Inc, Scarborough, ON, Canada; ⁵ Janssen-Ortho Inc, North York, ON, Canada; ⁶ Canada's Research-Based Pharmaceutical Companies, Ottawa, ON, Canada

PHP29

PATHOLOGY RELATED DIFFERENCES IN VARIANCE OF DRUG INSURANCE COST IN HOSPITAL STAYS : FEASIBILITY OF FIXED FUNDING IN PATHOLOGIES WITH REDUCED COST VARIANCE
Van Wilder P¹, Verplanken P^2
1 S.M.A.R.T, Zaventem, Belgium; ² IMS Health Belgium, Brussels, Belgium

PHP30

2006 DRUG PAYMENTS IN THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM: REIMBURSEMENT IMPLICATIONS
Baker JJ¹, Baker RW^2
1 Resource Group, Ltd, Pickton, TX, USA; ² University of Rochester, Rochester, NY, USA

PHP31

SENSIBLE FLEXIBILITY OR UNNECESSARY DUPLICATION? THE USE OF DECISION MODELLING IN NICE APPRAISALS
Hutton J¹, Pang F², Tolley K^3
1 MEDTAP International Inc, London, UK; ² Abbott Laboratories UK, Maidenhead, Berkshire, UK; ³ Ortho Biotech, High Wycombe, UK

PHP32

LOSS PROFILES DERIVED FROM ACTIVITY OF DAILY LIVING SCORES ATTRIBUTABLE TO HANDICAPS
Brézin A¹, Lafuma A², Fagnani F², Mesbah M³, Berdeaux G^4
1 Hopital Cochin, Paris, France; ² Cemka, Bourg-La-Reine, France; ³ Université de Bretagne-Sud, Vannes, France; ⁴ Alcon, Rueil-Malmaison, France

PHP33

SATISFACTION AMONG GERMAN PHYSICIANS – A REPRESENTATIVE EMPIRICAL STUDY
Bestmann B¹, Rohde V², Wellmann A³, Kuechler T^1
1 Reference Center Quality of Life in Oncology, Kiel, Schleswig-Holste, Germany; ² University of Giessen, Giessen, Hessen, Germany; ³ University of Bonn, Bonn, Noordrhein-Westf, Germany

PHP34

ENTERAL FEEDING IN THE COMMUNITY: A STUDY OF HEALTH ECONOMIC OUTCOMES USING THE GENERAL PRACTICE RESEARCH DATABASE (GPRD)
Pang F¹, Girod I², Saleh A², Knight H², Glencorse C¹, Edington J^3
1 Abbott Laboratories UK, Maidenhead, Berkshire, UK; ² MAPI Values UK, Macclesfield, Cheshire, UK; ³ Orion Technology, Gerrards Cross, Buckinghamshire

PHP35

RESOURCE USE AND COSTS OF PATIENTS RECEIVING ENTERAL NUTRITION IN PRIMARY AND SECONDARY CARE IN THE UK
Pang F¹, Girod I², Saleh A², Knight H², Glencorse C¹, Edington J^3
1 Abbott Laboratories UK, Maidenhead, Berkshire, UK; ² MAPI Values UK, Macclesfield, Cheshire, UK; ³ Orion Technology, Gerrards Cross, Buckinghamshire

PHP37

THE INFLUENCE OF CHANGE OF CO-PAYMENT TO THE USE OF ANTIBIOTIC AGENTS

Szalayova A
Ministry of Health, Bratislava, Slovak Republic

PHP38

USE OF PATIENT-REPORTED OUTCOMES IN EVALUATION OF HEART FAILURE DEVICE THERAPY: THE REGULATORY PERSPECTIVE

Muni NI¹, Pocock S², Berman MR¹, Yue LQ^1
1 U.S. Food and Drug Administration, Center for Devices and Radiological Health, Rockville, MD, USA; ² London School of Hygiene and Tropical Medicine, London, UK

PHP39

SELF-EFFICACY AND ACADEMIC ACHIEVEMENT OF THE FIFTH YEAR PHARMACY STUDENTS OF CHULALONGKORN UNIVERSITY, 2003.

Auamnoy T, Mekaroonreung S, Techawatcharatep C
Chulalongkorn University, Bangkok, Thailand

POB1

OBESITY AND THE RISK OF UPPER RESPIRATORY TRACT INFECTIONS
Williams TJ¹, Gilloteau I², Brouard R², Martinez C^1
1 GPRD Division, Medicines and Healthcare products Regulatory Agency, London, UK; ² Sanofi-Synthelabo Recherche, Paris, France

POB2

SOCIAL COST OF OVERWEIGHT AND OBESITY: SPESA STUDY
Mantovani LG¹, Belisari A², Carruba M^1
1 University of Milan, Milan, Italy; ² Novartis Farma S.p.a, Origgio, Varese, Italy

POB3

EVALUATION OF THE COST-UTILITY OF ORLISTAT (XENICAL) IN THE UK
McEwan P¹, Jones M¹, Farina C², Currie CJ^3
1 Cardiff University, Cardiff, Wales, UK; ² Roche Priducts Limited, Welwyn Garden City, Hertfordshire, UK; ³ Cardiff Research Consortium, Cardiff, Wales, UK

POB4

EVALUATING THE IMPACT OF WEIGHT LOSS ON QUALITY OF LIFE IN PATIENTS TAKING ORLISTAT AND ENROLLED IN THE MOTIVATION, ADVICE AND PRO-ACTIVE SUPPORT (MAP) PROGRAMME
Walker MD¹, Kolotkin R², Aultman R³, Wintfeld N⁴, Ruof J^3
1 Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK; ² Obesity and Quality of Life Consulting, Durham, NC, USA; ³ Hoffman-La Roche, Basel, Switzerland; ⁴ Hoffman-La Roche, Nutley, NJ, USA

POB5

COST AND QUALITY OF LIFE IN OBESITY
Micheletti S, Scalone L, Perelli Cippo P, Mantovani LG
University of Milan, Milan, Italy

POS1

COST- EFFECTIVENESS OF RISENDRONATE THERAPY COMPARED TO ALENDRONATE IN POST – MENOPAUSAL WOMEN AT HIGH RISK OF OSTEOPOROTIC FRACTURE: A TAIWAN ANALYSIS
Saadi R¹, Burge R², Ferko N³, Thompson M^3
1 Aventis Pharmaceuticals, Bridgewater, NJ, USA; ² Procter & Gamble Pharmaceuticals, Inc, Mason, OH, USA; ³ Innovus Research Inc, Burlington, ON, Canada

POS2

CLINICAL AND ECONOMIC IMPACT OF RISEDRONATE TREATMENT FOR POST- MENOPAUSAL OSTEOPOROSIS IN FRANCE
Burge R¹, Saadi R², Ferko N³, Thompson M³, Grima D^3
1 Procter & Gamble Pharmaceuticals, Inc, Mason, OH, USA; ² Aventis Pharmaceuticals, Bridgewater, NJ, USA; ³ Innovus Research Inc, Burlington, ON, Canada

POS3

TREATMENT COSTS AND DISEASE BURDEN OF PATIENTS WITH PAGET’S DISEASE
Briesacher B¹, Orwig D², Seton M³, Omar M⁴, Kahler K^4
1 University of Massachusetts, Worcester, MA, USA; ² University of Maryland, Baltimore, MD, USA; ³ Massachusetts General Hospital, Boston, MA, USA; ⁴ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

POS4

COST-EFFECTIVENESS OF BONE STIMULATORS IN THE CONSERVATIVE TREATMENT OF STABLE NONUNION FRACTURES
Schultz M¹, Oremus M¹, Whitman CS², Conway JD^3
1 Pharmaccess Inc, Westmount, QC, Canada; ² Hugh Chatham Memorial Hospital, Elkin, NC, USA; ³ Sinai Hospital of Baltimore, Baltimore, MD, USA

POS5

MEDICO-ECONOMIC EVALUATION OF VERTEBRAL FRACTURE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN
Reygrobellet C¹, Maurel F¹, Jamonneau I², Liu-Leage S², Alfonsi A², Le Pen C³, Roux C^4
1 Aremis Consultants, Paris, France; ² Laboratoire Lilly, Suresnes, France; ³ Aremis Consultants and Paris Dauphine University, Paris, France; ⁴ Cochin Hospital, Paris, France

POS6

COST-EFFECTIVENESS OF MIACALCIC IN TREATMENT OF PAIN DUE TO OSTEOPOROTIC VERTEBRAL FRACTURE
Yevstigneeva L¹, Lesnyak Y², Lesnyak O^1
1 Ural State Medical Academy, Yekaterinburg, Russia; ² Lanotech company, Yekaterinburg, Russia

POS7

PERSISTENCE AND COMPLIANCE WITH BISPHOSPHONATE THERAPY AMONG POST-MENOPAUSAL OSTEOPOROTIC WOMEN
Cramer J¹, Amonkar MM², Hebborn A³, Suppapanya N^2
1 Yale University, West Haven, CT, USA; ² GlaxoSmithKline, Collegeville, PA, USA; ³ Hoffmann-La Roche, Nutley, NJ, USA

POS8

PERSISTENCE WITH BISPHOSPHONATE THERAPY AND THE IMPACT OF DOSING FREQUENCY IN PATIENTS WITH POST-MENOPAUSAL OSTEOPOROSIS
Penning-van Beest FJA¹, Goettsch WG², Erkens JA², Herings RMC^2
1 PHARMO Institute, Utrecht, Utrecht, Netherlands; ² PHARMO Institute, Utrecht, Netherlands

POS9

EPIDEMIOLOGY OF OSTEOPOROSIS IN THE NETHERLANDS (1993-2002)
Panneman MJM¹, Goettsch WG¹, Kramarz P², Herings RMC^3
1 PHARMO Institute, Utrecht, Netherlands; ² Pfizer, Walton Oaks, UK; ³ PHARMO Institute / Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

PPN13

THE UNDER TREATMENT OF DEPRESSION IN CHRONIC PAIN

Sampson J, Marsh B
VA Medical Center, Gainesville, FL, USA

PPN1

ESTIMATING THE INCIDENCE AND COSTS OF TREATING ADVERSE EVENTS IN PATIENTS TREATED WITH STRONG OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN
Morris J, Berry P
Napp Pharmaceuticals, Cambridge, UK

PPN2

RESOURCE UTILISATION OF PATIENTS WITH CHRONIC PAIN CONDITIONS BEFORE AND DURING TREATMENT WITH LONG-ACTING OPIOIDS IN GERMANY
Burkowitz J, Brüggenjürgen B
Alpha Care GmbH, Celle, Germany

PPN3

AN OBSERVATIONAL STUDY OF INTRAVENOUS PATIENT-CONTROLLED ANALGESIA RESOURCE UTILIZATION AT AN ACADEMIC MEDICAL CENTER
Zhang M¹, Viscusi E², Costello A², Vallow S³, Johnson N^4
1 Ortho-McNeil Pharmaceutical, Raritan, NJ, USA; ² Thomas Jefferson University, Philadelphia, PA, USA; ³ Janssen Medical Affairs, LLC, Titusville, NJ, USA; ⁴ Outcomes Research and Design, Inc, Houston, TX, USA

PPN4

COST-EFFECTIVENESS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL IN TREATMENT OF SUBACUTE LOW BACK PAIN IN A DUTCH HEALTH CARE SETTING
Nuijten M¹, Poulsen Nautrup B^2
1 Medtap International, Jisp, Netherlands; ² Gruenenthal, Aachen, DE, Germany

PPN5

PROSPECTIVE ASSESSMENT OF THE HEALTH AND ECONOMIC BURDEN OF NEUROPATHIC PAIN
Annemans L¹, Van Campenhout H², Maeyaert J³, Morlion B^4
1 HEDM, Meise, Belgium; ² Pfizer Belgium, Brussels, Belgium; ³ Heilig Hart Kliniek, Eeklo, Belgium; ⁴ UZ Gasthuisberg, Leuven, Belgium

PPN6

BURDEN OF ILLNESS SURVEY IN PATIENTS WITH PAINFUL NEUROPATHIC DISORDER (PNDS) IN GERMANY.
Tölle TR¹, Stridde E^2
1 Technische Universität München, München, Germany; ² Pfizer GmbH, Karlsruhe, Germany

PPN7

USE OF THE NEUROPATHIC PAIN SCALE IN AN INTERNATIONAL STUDY
Nadjar A¹, Conway K¹, Jensen MP², Galer BS³, Hutchings A^4
1 Mapi Research Institute, Lyon, France; ² University of Washington, Seattle, WA, USA; ³ Endo Pharmaceuticals, Inc, Chadds Ford, PA, USA; ⁴ GlaxoSmithKline, Greenford, UK

PPN8

RESPONSIVENESS OF THE SHUTTLE WALKING TEST COMPARED WITH DISEASE SPECIFIC AND GENERIC OUTCOME MEASURES IN PATIENTS WITH CHRONIC BACK PAIN
Rivero-Arias O¹, Campbell H¹, Gray A¹, Johnston K¹, Fairbank JC², Frost H², Spine Stabilisation Trial S^3
1 Oxford University, Oxford, UK; ² Nuffield Orthopaedic Centre, Oxford, UK; ³ Spine Stabilisation Trial Office, Oxford, UK

PPN9

AGREEMENT BETWEEN PATIENTS’ AND CLINICIANS’-REPORTED OUTCOMES IN 3 CHRONIC DISEASES
Chassany O¹, Le Jeunne P^2
1 Assistance Publique – Hopitaux de Paris, Paris, France ; ² Thales observatoire epidemiologique, Boulogne, France

PPN10

QUANTIFICATION OF SUSPECTED ADDICTION TREATMENT OF NARCOTIC ANALGESICS USING PRESCRIPTION SEQUENCE ANALYSIS: EXPERIENCE OF A STATE-BASED WORKER’S COMPENSATION SYSTEM
Islam S¹, Hassan MK¹, Doyle E¹, Becker J², Weikle P², Ducatman A^1
1 West Virginia University, Morgantown, WV, USA; ² West Virginia Worker’s Compensation Commission, Charleston, WV, USA

PPN11

DEVELOPMENT OF AN INSTRUMENT TO CAPTURE EASE-OF-CARE OUTCOMES IN PATIENTS TREATED WITH PCA DELIVERY SYSTEMS
Harding G¹, Vallow S², Leidy NK¹, Zhang M³, Olson W⁴, Hewitt D⁴, Viscusi E^5
1 MEDTAP International Inc, Bethesda, MD, USA; ² Janssen Medical Affairs, L.L.C, Titusville, NJ, Afghanistan; ³ Ortho-McNeil Pharmaceutical Inc, Raritan, NJ, USA; ⁴ Ortho-McNeil Pharmaceutical Inc; ⁵ Thomas Jefferson University Department of Anesthesiology

PPN12

DEVELOPMENT OF TWO INSTRUMENTS TO CAPTURE EASE-OF-CARE OUTCOMES IN HEALTH-CARE PROVIDERS WHO CARE FOR PATIENTS TREATED WITH PCA DELIVERY SYSTEMS
Harding G¹, Vallow S², Leidy NK¹, Zhang M³, Olson W³, Hewitt D³, Polomano R^4
1 MEDTAP International Inc, Bethesda, MD, USA; ² Janssen Medical Affairs, L.L.C; ³ Ortho-McNeil Pharmaceutical, Inc; ⁴ Pennsylvania State College of Medicine

PRS1

WITHDRAWN

PRS2

COST OF CHRONIC BRONCHITIS (CB) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN FRANCE : THE BRONCHECO STUDY
Huchon G¹, Crochard A², Vergnenegre A³, Lenne X⁴, Chidiac C⁵, Neukirch F⁶, Boucot I^2
1 Hopital Hotel-Dieu, Paris, France; ² GlaxosmithKline, France; ³ Hopital du Cluzeau, France; ⁴ CRESGE-LABORES, France; ⁵ Hopital de la Croix Rousse, France; ⁶ Hopital Bichat, France

PRS3

PHARMACOECONOMY AND ANTIBIOTIC TREATMENT WITHIN THE SLOVAK REPUBLIC
Tesar T¹, Foltan V, Petrzalka A¹, Banasova K^1
1 University Comenianae, Bratislava, Slovak Republic

PRS4

COST OF TREATMENT AND REIMBURSEMENT OF HOSPITALIZED COMMUNITY-ACQUIRED PNEUMONIA WITH I.V. MOXIFLOXACIN COMPARED TO STANDARD ANTIBIOTIC TREAMENT IN GERMANY
De Zeeuw J¹, Pfeil T², Thate-Waschke IM³, Ernen C², Daniel D², Bauer TT¹, Schlosser BM¹, Rychlik R^2
1 Bergmannsheil Hospital, University of Bochum, Bochum, Germany; ² Institute of Empirical Health Economics, Burscheid, Germany; ³ Bayer Vital, Leverkusen, Germany

PRS5

COSTS OF COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITAL’S PERSPECTIVE IN GERMANY – FINAL RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY
Bauer TT¹, Schlosser BM¹, Ernen C², Thate-Waschke IM³, Pfeil T², Daniel D², Rychlik R^2
1 Bergmannsheil Hospital, University of Bochum, Bochum, Germany; ² Institute of Empirical Health Economics, Burscheid, Germany; ³ Bayer Vital, Leverkusen, Germany

PRS6

A CANADIAN COST ANALYSIS OF 4 RANDOMIZED DOUBLE-BLIND ACTIVE COMPARATOR TRIALS WITH TELITHROMYCIN IN ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB) AND COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Tsakonas E¹, Stewart J¹, Chang J^2
1 Aventis Pharma, Laval, QC, Canada; ² Aventis Pharma US, Bridgewater, NJ, USA

PRS7

THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE HAS A NEGATIVE IMPACT ON THE QUALITY OF LIFE OF THE PATIENT: THE RESULTS OF THE EPIDEPOC STUDY
García M¹, Carrasco P¹, Jiménez R¹, De la Fuente S², Gobbart E³, Gil A^1
1 Rey Juan Carlos University, Mostoles (Madrid), Spain; ² Pfizer S.A. Spain, Madrid, Spain; ³ Boehringer Ingelheim S.A, Sant Cugat del Valles (Barcelona), Spain

PRS8

IMPACT ON USE AND COST OF MEDICINES OF EXPANDED DRUG COVERAGE VIA POSITIVE LIST IN THE PHILIPPINES
Valera M
Philippine Health Insurance Corporation, Manila, Philippines